Reading HRMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HRMY free→Reading HRMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HRMY free→QuarterlyIQ Insights · HRMY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer On April 14, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) announced that Sandip Kapadia, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of April 14, 2026 to pursue other career opportunities. In connection with his departure from t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Operating Officer; Resignation of Director On April 2, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) named Peter Anastasiou the Company’s Senior Executive Vice President and Chief Operating Officer (“COO”), effective April 2, 2026. In connection with his appointment as COO, on April 2, 2026, Mr. Anastasiou provided n…
Results of Operations and Financial Condition. On February 24, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On October 23, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary net product revenue for the third quarter of 2025. In addition, the Company provided updated guidance related to 2025 net product revenue. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference . Note Regarding Forward-Looking Statements Certain state…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.